Project Call 1.0 Proposal Selected by NIIMBL Governing Committee

Durham, NC (USA) – August 30, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, and the University of North Carolina Wilmington (UNCW), North Carolina’s globally-minded research and development university, today announce they have been awarded an educational grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), an organization comprised of companies, educational institutions, nonprofits, and state governments dedicated to accelerating biopharmaceutical manufacturing innovation, developing industry standards, and educating and training a pipeline of skilled workers for the field’s abundant well-paying jobs. The grant will fund the UNCW program “Partnership for Workforce Development in the Biopharmaceutical Industry,” which will be co-developed and taught by Alcami subject matter experts.

Durham, NC (USA) – July 18, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced a renewed partnership with the Wisconsin Department of Natural Resources (DNR) to revitalize and repair the Hank Aaron State Trail in Milwaukee, Wisconsin, and the Pike Lake Hiking Trail in Hartford, Wisconsin. Volunteers from Alcami’s Germantown, Wisconsin Center of Excellence for active pharmaceutical ingredient (API) development, scale-up, and commercialization will work alongside Wisconsin DNR trail coordinators and park superintendents to renovate the popular state trails.

Durham, NC (USA) – June 14, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, announced today its $15,000 donation to the Wilmington, North Carolina Fire Department (WFD) to help fund IvyGene® cancer screenings for firefighters. Wilmington Mayor Bill Saffo, Mayor Pro-tem Margaret Haynes, Deputy Fire Chief Jon S. Mason, and other prominent city officials accepted the donation at an invitation-only commemorative event Wednesday, June 13, 2018, at Alcami’s Wilmington state-of-the-art advanced laboratory services and oral solid dose formulation and manufacturing facilities.

Durham, NC (USA) – June 13, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced the expanded deployment of its Extended Workbench laboratory services program to support the ongoing manufacturing and development of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension). ZILRETTA is the first U.S. Food and Drug Administration (FDA) approved product from Flexion Therapeutics, Inc., a Massachusetts-based biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). Flexion utilized Alcami’s Extended Workbench to support ZILRETTA from Phase 2 clinical trials through commercial launch and is using the program for the release and stability testing of commercial batches.

Durham, NC (USA) – June 1, 2018 – Alcami Corporation (“Alcami” or the “Company”), a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced it has reached an agreement to be acquired by Madison Dearborn Partners, LLC (MDP). MDP, a leading private equity firm based in Chicago, will acquire a majority ownership position in Alcami from existing shareholder Ares Capital Corporation (NASDAQ: ARCC) (“Ares Capital”). Alcami’s management team, led by Chief Executive Officer, President, and Chairman, Dr. Stephan Kutzer, will continue to guide the Company. The transaction is expected to be completed in the third quarter of 2018, pending customary closing conditions.

Durham, NC (USA) – May 8, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announces the advancement of the drug development process with the company’s new, dramatically-reduced analytical testing turnaround times. Alcami continues to set the industry standard with its analytical testing offering, and through operational excellence, streamlined processes, and technical knowledge and expertise, has reduced timelines by up to 30 percent.

“At Alcami, your timeline is our timeline,” said Alcami Chief Commercial Officer, Syed T. Husain. “We have made efficient, rapid, and reliable turnaround time a priority, as part of our commitment to bring our clients’ products through the clinic and to market first, while delivering the highest level of quality and finest customer experience in the industry.”

Durham, NC (USA) – May 3, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announces the Missouri House of Representatives and St. Louis Mayor Lyda Krewson will honor Alcami with a resolution and letter of commendation, recognizing the company’s operational excellence, celebrating its industry-leading accomplishments, and applauding the organization for improving St. Louis citizens’ quality of life.

State Representative Steven Roberts of St. Louis District 77 and City of St. Louis Chief Technology Officer Robert Gaskill-Clemons will issue the proclamation and congratulatory letter Tuesday, May 8, 2018, 2:00 p.m., at an invitation-only customer open house event inside Alcami’s state-of-the-art Center of Excellence for analytical testing.

Dr. Stephan Kutzer, CEO, President and Chairman of Alcami Corporation, sits down with the Triangle Business Journal to discuss company growth, jobs with new Triangle HQ.

For contract development and manufacturing organization Alcami, moving a planned headquarters expansion from Wilmington to the Triangle was just the beginning of continued investment in North Carolina, other U.S. bases and abroad, says President, Chairman and CEO Stephan Kutzer.

While Alcami's headquarters expansion was originally planned for Wilmington as the company's previous base and from a "sheer size" perspective, it decided last year to move its headquarters to the Triangle for reasons including recruitment and growth in highly technical areas and presence in a hub of the pharmaceutical industry crucial to attracting investors and customers, according to Kutzer. 

Durham, NC (USA) – March 15, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, and Triangle Residential Options for Substance Abusers, Inc. (TROSA), a Durham-based innovative, multi-year residential program that enables substance abusers to be productive, recovering individuals by providing comprehensive treatment, work-based vocational training, education, and continuing care, today announce Alcami’s donation of $10,000 to the nonprofit. Alcami’s gift will fund TROSA’s technology needs for its recently established Comprehensive Care Center.

Experts from Alcami’s Germantown, Wisconsin active pharmaceutical ingredient (API) Center of Excellence teamed up with Germantown High School engineering and honors biology students Monday, February 26, 2018, in Germantown, Wisconsin, for a Day of STEM (Science, Technology, Engineering, and Math) – part of an ongoing series of educational presentations promoting the importance of careers in science, technology, engineering, and math.